Drugs / Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05410717 | Jun 2022 → Jun 2030 expected | endometrial cancer, ovarian carcinoma, testicular cancer | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410717 ↗ |
| Action | Deplete | “test the quality and killing activity of the Claudin6, GPC3, Mesothelin, or AXL-CAR-NK cells” NCT05410717 ↗ |
| Modality | Cell therapy | “CAR-NK cell therapy” NCT05410717 ↗ |
| Route | Other | “transplant back the patients via systemic or local infusions (via artery or intra-tumor)” NCT05410717 ↗ |